Immunostimulants drugs - versus anti-inflammatoty and immuno-therapy - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 4.22 [0.33, 53.77]< 10%1 study (1/-)13.6 %NAnot evaluable crucial-
deaths 1.36 [0.76, 2.42]< 10%3 studies (3/-)14.9 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 3.26 [0.62, 17.12]< 10%1 study (1/-)8.2 %NAnot evaluable crucial-
clinical deterioration 1.30 [0.42, 4.02]< 10%2 studies (2/-)32.2 %lownot evaluable highimportant-
clinical improvement 1.34 [0.94, 1.90]> 136%3 studies (3/-)94.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.86 [1.24, 6.62]> 10%1 study (1/-)99.3 %NAnot evaluable important-
clinical improvement (28-day) 4.26 [1.10, 16.44]> 10%1 study (1/-)98.2 %NAnot evaluable important-
clinical improvement (7-day) 1.83 [0.41, 8.14]> 10%1 study (1/-)78.5 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.34 [0.94, 1.90]> 136%3 studies (3/-)94.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.67 [0.14, 3.26]< 10%1 study (1/-)69.0 %NAnot evaluable important-
mechanical ventilation 1.92 [0.35, 10.65]< 10%2 studies (2/-)22.9 %lownot evaluable highimportant-
viral clearance 3.59 [1.15, 11.21]> 10%2 studies (2/-)98.6 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 1.74 [1.10, 2.75]> 10%1 study (1/-)99.1 %NAnot evaluable important-
viral clearance by day 14 1.74 [0.71, 4.29]> 10%1 study (1/-)88.7 %NAnot evaluable important-
viral clearance by day 7 2.32 [1.14, 4.73]> 10%2 studies (2/-)99.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 4.54 [0.20, 105.23]< 10%1 study (1/-)17.6 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.